Overview

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Status:
Recruiting
Trial end date:
2022-04-25
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and toxicity of anlotinib in patients with platinum resistant or refractory ovarian cancer
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University